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Introduction
Despite the continuous development of new cancer treatment strategies, 
including optimization of already known drugs, as well as development 
of new targeted therapies, too many cancer patients still experience 
recurrence of their disease with subsequent disease related deaths. 
It is thus clear that in order to lower the number of deaths, there is an 
urgent need for the development of more effective treatment strategies 
including the introduction of new procedures for optimal prediction of 
response to treatment. Anticancer drug treatment given either alone 
or in various combinations includes different types of chemotherapy 
(cytotoxic drugs), endocrine therapy, immunotherapy and recently 
specified targeted therapies. In most metastatic cancer diseases, the 
objective response rates (complete and partial responses) to any of 
these treatment options are far from 100 %. This means that a significant 
number of cancer patients receive chemotherapy with no other effect 
than systemic toxicity.
While detection of estrogen and progesterone 
receptors in breast cancer is a well-established 
routine method to predict objective response 
to endocrine therapy, there is at present no 
accepted method to determine whether a 
cancer patient will benefit from chemotherapy 
in its broad sense. If such a method existed, 
it would allow for a tailor-made approach 
resulting in individualized treatment. This 
would also imply that for those patients having 
resistant tumors, such an approach would not 
only spare them from side effects induced by ineffective chemotherapy, 
but would also have a major impact on the economics of the health care 
system in terms of savings of expenses related to otherwise ineffective 
treatment. Furthermore, it is now clear that predictive molecular assays 
must be devised before the initiation of clinical trials for new targeted 
anticancer agents. Use of predictive markers will increase the specificity 
and usefulness of these drugs and provide a meaningful clinical 
evaluation in the population of patients most likely to benefit from the 
treatment. Thus, the field of cancer drug discovery clearly needs to 
turn greater attention to the problem of identifying responsive/resistant 
subsets of patients early in the development process and needs to 
utilize the knowledge obtained through molecular and cellular studies 
of cancer biology. 
DNA Biomarkers 
At the cellular level cancer is a genetic disease and the tumor cells 
have acquired genetic changes that are responsible for the multistep 
process that drives the malignant transformation (1). The cancer 
specific genetic changes may lead to altered mRNA and protein levels 
and may represent the most important mechanism by which the tumor 
can permanently acquire new functionality. The acquired specific 
genetic changes in the cancer cells will however, not be present in the 
non-malignant cells of the patient. Therefore, it is obvious to exploit the 
specific genetic changes of the tumor cells as diagnostic, prognostic 
and especially predictive tools in the management of cancer patients. 
The malignant transformation is driven by inactivation of tumor suppressor 
genes combined with activation of proto-oncogenes. The inactivation of 
tumor suppressor genes can occur by a variety of mechanisms, including 
physical deletion, point mutation and/or methylation - all leading to loss 
of function. Proto-oncogenes, on the other hand, can be activated 
by amplification, point mutation or structural rearrangements. Minor 
changes include point mutations and smaller intragenic deletions and 
duplications and the DNA amount involved 
ranges from a single base pair to several 
millions of base pairs. These changes 
can be studied by sequencing, LOH (loss 
of heterozygosity) allelic imbalances (AI) 
and/or PCR based techniques combined 
with blotting techniques. The methods are 
precise for the detection of point mutations, 
but larger deletions and duplications are 
not revealed. Only by comparing the DNA 
sequence of the cancer cells with the 
normal cells of the patient, is it possible 
to distinguish point mutations from single nucleotide polymorphisms 
(SNPs). Polymorphism is a normal genetic variation present in the 
population and thus not directly linked to the cancer. Further, the gene 
function may be influenced by epigenetic factors, e.g. methylation.
The major genetic changes include large stretches of DNA, from 
several thousands to millions of base pairs, and may, depending on 
methodology, be detected as structural rearrangements or copy number 
changes (CNC). The techniques described above for detection of minor 
genetic changes cannot reveal the major genetic changes and vice 
versa. The major genetic changes can be studied by CGH (comparative 
genomic hybridization), array-CGH and/or FISH (fluorescence in situ 
hybridization). Using FISH technique, structural rearrangements can be 
detected as chromosome translocations and the copy number changes 
are seen as amplifications, deletions, and duplications. FISH methods 
for detection of these chromosome aberrations were initially developed 
for cytogenetic specimens (Fig.1) but have later been refined to cut 
sections of paraffin embedded tissue (Fig. 2). 
“	...it	is	now	clear	that	predictive	
	molecular	assays	must	be		
	 devised	before	the	initiation	of	
	 clinical	trials	for	new	targeted	
	 anticancer	agents.”
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The FISH technique comprises hybridizing fluorescent labeled probes 
with target DNA of the cancer tissue. The gene directed probe is 
preferentially 200-400 kilobase pairs in length and includes the cancer 
related gene and flanking regions. When selecting the genomic clones 
for diagnostic use, the gene of interest should be located at a position 
that excludes or minimize presence of flanking genes that potentially 
could be related to cancer.
Gene copy number changes can be viewed in the nuclei of a tissue 
and counted directly. A normal cell will contain 2 gene copies and a 
deviation from this number is indicative of an abnormal cell. However, 
due to the fact that cut sections of tissue are 4-6 µm in thickness and 
the nuclei of a cancer cell is often 10 µm, this simple relationship is not 
applicable for cut sections. Therefore, a reference probe is added to the 
probe mix and the ratio between the gene probe (labeled in red) and 
the reference probe (labeled in green) is scored. Inclusion of a reference 
probe has further the advantage that gene copy number changes due 
to polyploidization of the whole genome can be distinguished from 
amplifications and allows also the detection of deletions. As reference 
probe, compensating for the ploidy level of the tumor, the centromere 
of the chromosome that the gene of interest resides on is often used, 
although it could be any other region of the genome. The signals are 
scored using a fluorescence microscope equipped with filters that are 
suited for the red and green fluorochromes. A total of 60 nuclei are 
normally scored, although alternative counting methods can be used 
(3). Specific details and variations of the FISH method is described in 
Nielsen et al. (2).
Predictive DNA biomarkers can be found by either screening cancer 
cell lines for amplified genes (e.g. HER2), or by studying the gene that 
is the target for the drug (e.g. TOP2A) or by studying genes involved 
in the pathway of the drug (e.g. EGFR). A number of examples are 
described below.
One of the most well-established biomarker is the HER2 used for 
selection of patients for treatment with antibodies directed against HER2. 
Initially, HER2 (alias of ERBB2) gene amplifications were studied using 
Southern blotting technique (4), followed by additional information on the 
mRNA and protein level (5), and eventual leading to the development of 
a treatment targeting the product of the genetic disorder of the tumor 
(6). Because the HER2 protein is the therapeutic target, much debate 
has been devoted to the question about the best use of the different 
methods, and it is now generally agreed upon (7) that both FISH or 
immunohistochemistry (IHC) may be used for the assessment of HER2 
status in breast cancer. HER2 may, however, be an exceptional case 
with a very high correlation between the gene copy number studied by 
FISH and the protein immunoreactivity studied by IHC and precaution 
should be taken in generalization from the HER2 case.
Located very close to the HER2 gene on chromosome 17 is the TOP2A 
gene. The gene codes for topoisomerase IIa which is the target for a 
group of widely used chemotherapeutic drugs, the anthracyclines. The 
link between the biomarker and the drug was first described in an in vitro 
grown cancer cell line (8) having amplification of the TOP2A gene and 
overexpression of the protein, and initially is was reported that the gene 
copy number and the mRNA and protein level correlated in this lung 
cancer cell line (9). Later, studies including samples from breast cancer 
Figure 2. TOP2A gene probe in red and centromere 17 reference probe in 
green hybridised to breast cancer tissue (left) showing amplification and deletion 
(middle) and to a metaphase spread of a cell line showing the distribution of the 
amplified signals onto many different chromosomes (right).
Figure 1. Localisation of TOP2A gene probe in red and centromere 17 reference 
probe in green schematically on an ideogram (left) and on metaphase spread 
from normal human blood.
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patients, have shown that TOP2A gene aberrations are predictive for 
the outcome of treatment with anthracyclines (10, 11), however a direct 
correlation between gene copy number and protein amount has not 
been established (12, 13). In contrast to HER2, the DNA and protein 
measurements are thus not interchangeable in the case of TOP2A and 
anthracyclines. This relationship is further complicated by the existence 
of TOP2A deletions.
The epidermal growth factor receptor (EGFR) is amplified or 
overexpressed in many cancers, including non-small-cell lung cancer 
and colorectal cancer, and is targeted by EGFR inhibitors. Much 
effort has been devoted to finding a biomarker that can be used to 
predict the outcome of treatment with EGFR inhibitors. Initially, IHC, 
assessing the EGFR protein, was used as a diagnostic tool, and then 
EGFR mutations were reported, and eventually gene copy number 
changes were described. Among the various tests developed to predict 
objective response to EGFR inhibitors, the EGFR-FISH test seems to be 
the most promising (14), however only very few studies have included 
and compared all 3 methods (15) and a consensus has not yet been 
reached regarding the use of biomarkers for selection of therapy with 
EGFR inhibitors. The consensus is also hampered by the fact that 
different drugs and different cancer types are being studied using 
different biomarkers (protein, point mutation or major genetic change), 
different methodologies for the biomarker and even different cut-offs in 
defining the discrimination between normal (negative) and abnormal 
(positive) cases. 
The lesson learned from the EGFR puzzle must be that future studies 
of biomarkers for targeted drugs should be well designed and include 
pilot studies to determine the methodology and cut-off levels to be used 
in the confirmatory clinical studies. In addition, if the pilot studies cannot 
point to the right biomarker, both protein and DNA measurements should 
be included in the relevant clinical trials. Also, it is important to know that 
point mutations and amplifications, although both being alterations of 
the DNA, may not provide the same biological information. Eventually, it 
may be a combination of 2 or more techniques that should be used to 
determine the biomarker status.
RNA Biomarkers
Genetic mutations, genomic losses, amplifications and epigenetic 
changes including those that control success or failure of chemotherapy, 
are the driving forces in cancer. The first and currently most easy-
accessible reporters of these genetic and epigenetic alterations are 
the downstream transcripts that are under their control. At present, 
the most commonly used methodology to study expression of multiple 
genes in cancer tissue is gene expression microarrays. Current gene 
expression arrays contain, on a single array, multiple detection probes 
to all annotated mRNA species of the human genome (>25K mRNA 
species). Successful gene expression analysis (16-22) on microarrays 
and subsequent identification of predictors of disease states involve 
various steps. In general, fresh-frozen tumor material is used for gene 
expression analysis since high quality RNA is needed for this to be 
successful. However, today, it is also possible to extract RNA from 
formalin-fixed paraffin embedded material. It should be mentioned, 
however, that this RNA is fragmented and partially chemically modified 
and therefore currently less useful for microarray discovery studies. This 
material is, however, highly suited for validations of gene signatures 
using e.g. quantitative RT-PCR analysis of selected genes.
With regard to the clinical significance of gene expression profiling, the 
breakthrough came from Stanford Laboratory who identified based on 
global gene expression five major subgroups in clinical breast cancer 
specimens (23). Thus, within both the ER-positive (i.e. luminal A and B) 
and –negative (i.e. basal and normal-like) breast cancers at least two 
biologically distinct subgroups are present that are different with regard 
to aggressiveness (24, 25) and response to neo-adjuvant paclitaxel 
containing chemotherapy (26). After these first landmark observations 
the field has rapidly progressed, and gene signatures associated 
with endocrine therapy resistance (27), and chemotherapy response 
(Martens et al., manuscript in preparation) (28-30) have been revealed 
and predictors of bone and lung relapse uncovered (31-33). For 
clinical use, the most promising assays are gene expression signatures 
predicting disease recurrence in breast cancer patients with lymph-node 
negative disease. Starting with the 70-gene signature predicting disease 
outcome in young patients (34, 35), a wound-healing signature (36), a 
Nottingham Prognostic Index (37) and genomic grade signature (38) 
predicting disease recurrence have been identified. A robust 76-gene 
signature was developed for the prediction of distant metastasis 
in lymph-node negative patients irrespective of age and hormone 
receptor status (39). In addition to this, in patients with lymph node-
negative and estrogen receptor-positive disease receiving adjuvant 
endocrine therapy with tamoxifen, a 21-gene recurrence score (40) 
and a 2-gene signature, the Interleukin 17B receptor- Homeobox B13 
(IL17BR-HOXB13) ratio (41) predicting disease recurrence have been 
identified. Of these signatures some have been validated (42, 43) but 
only the 70-gene signature from Amsterdam and the 76-gene signature 
from Rotterdam have been validated in large independent multi-centric 
cohorts (44-46). This has allowed the initiation of prospective evaluation 
of the performance of selected prognostic gene signatures in Europe 
and in the US. Furthermore, for a specific validated multi-gene classifier 
the FDA recently approved the technology to be used as a prognostic 
tool in the clinic.
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In conclusion, various predictive gene signatures have been identified 
while others are being developed. Even though most of them still 
need independent validation, there is no dispute that predictive gene 
signatures are likely to be used for therapy decisions in the future.
Protein Biomarkers 
“Proteomics” is a rapidly developing area of cancer research which 
promises to have an enormous impact on prediction of therapy response 
in the individual patient. Gel-based and high throughput proteomic 
technologies, including two-dimensional gel electrophoresis, one- and 
two-dimensional liquid chromatography, and proteomic microarrays in 
combination with mass spectrometry (MS) are currently the main tools 
available to mount a search for cancer protein biomarkers. Proteomic 
technologies are used for identification of new markers as well as for 
studying potential differences in the processing of already established 
protein markers. The hypothesis is that the protein biosynthesis 
machinery of cancer cells is significantly changed relative to normal 
cells in relation to the production, degradation and post-translational 
processing of proteins. 
When the protein marker is identified, several different methodologies 
can be applied when validating the marker in clinical material. The more 
common methods include immunohistochemical staining of frozen or 
formalin fixed tissue, and tumor tissue protein extractions followed by 
immunological methods such as Enzyme-linked Immunosorbent Assay 
(ELISA) or Radio- Immuno Assay (RIA). The latter methods can also be 
applied on bodily fluids such as plasma, serum, urine or saliva. 
At present a number of proteins, e.g. ER, PgR, ERBB2, and c-kit 
have proved their value in predicting clinical sensitivity/resistance to 
targeted cancer therapy. However, no protein measurement is in routine 
use for prediction of sensitivity/resistance to conventional cytotoxic 
chemotherapy. 
Since most types of chemotherapy induces cell death by activating 
the apoptosis machinery in the cancer cells, many attempts have been 
made to relate amount of anti-apoptotic proteins in the cancer cells to 
degree of sensitivity/resistance to chemotherapy. We have chosen to 
report on one of these proteins, Tissue Inhibitor of Metalloproteinases 
type 1 (TIMP-1), since this protein has recently been shown to be 
involved in cellular protection against apoptosis and thereby resistance 
to chemotherapy (47). The TIMP1 gene is located on chromosome 
Xp11.23-11.4 and codes for a soluble 28.5 kDa glycoprotein that 
consists of 184 amino acids in the mature form. The TIMP-1 protein can 
be present as a precursor form, as an unbound protein (free TIMP-1) 
or as a 1:1 stoichiometric complex with proMMP-9 or any of the non 
membrane-bound active matrix metalloproteinases (MMPs), in the latter 
case inhibiting the proteolytic activity of the enzymes (for review see 
Würtz et al (48)). 
TIMP-1’s inhibition of tissue remodeling processes, such as inflammation, 
wound healing, and cancer invasion, has mainly been ascribed to its 
inhibition of MMP mediated proteolytic activity. In contrast, the anti-
apoptotic function of TIMP-1 has been shown to be MMP-independent. 
The MMP independent anti-apoptotic pathway was first demonstrated in 
a study of Burkitt’s lymphoma cell lines (49, 50). In this study, a positive 
correlation between TIMP-1 expression and resistance to apoptosis 
was shown. Addition of recombinant TIMP-1 resulted in inhibition of 
apoptosis, and addition of anti-TIMP-1 antibodies to neutralize secreted 
TIMP-1 resulted in a four-fold increase in induction of apoptosis. Of 
specific interest was that reduced or alkylated TIMP-1, completely 
devoid of all MMP inhibitory activity, effectively inhibited apoptosis in 
Burkitt’s lymphoma cells (49, 50).
Recently, TIMP-1 was shown to interact with CD63 in MCF10A cells (51). 
CD63 is a member of the tetraspanin family. Of particular interest was 
that the interaction of TIMP-1 with CD63 inhibited caspase mediated 
apoptosis. Binding of TIMP-1 to the cell surface initiates a signal 
transduction cascade through Ras. Ras increases phosphorylation 
of ERK, and activates the Raf-1/tyrosine kinase/mitogen-activated 
protein kinase (MAPK) and the phosphoinositide 3-kinase (PI3K) signal 
pathways leading to stimulation of Cyclin D1 expression. By constitutive 
activation of focal adhesion kinase (FAK) and/or through the PI3 kinase, 
which phosphorylates Akt and Bad, TIMP-1 increases the expression of 
the anti-apoptotic protein Bcl-XL and thereby preventing activation of the 
caspase cascade (52). Fig. 3 shows part of the intracellular signaling 
induced by TIMP-1 binding to CD63. 
In cell culture-based systems, lack of cancer cell TIMP-1 expression 
results in increased sensitivity towards chemotherapy (47), suggesting 
a potential use of TIMP-1 tumor tissue measurements in predicting 
sensitivity/resistance to chemotherapy in clinical cancer. Indeed, we 
have recently published that women with metastatic breast cancer 
and high tumor tissue TIMP-1 values show an objective response to 
antracycline-based chemotherapy of 0% while patients with low TIMP-1 
levels show an objective response rate of 45% (53). 
Similarly, in a study including patients with metastatic colorectal cancer 
who received 5FU, leucovorin and irinotecan, high plasma TIMP-
1 levels (dichotomized by the median plasma TIMP-1 value) were 
indicative of low probability of objective response to chemotherapy 
(54). This decreased probability of obtaining an objective response 
to chemotherapy in plasma high TIMP-1 patients was reflected in a 
significantly decreased time to progression and overall survival of the 
patients with 62% of TIMP-1 low patients being alive at 24 months 
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following treatment compared with only 7% of patients with high plasma 
TIMP-1 levels being alive at this time point. The Gastrointestinal Cancer 
Group and the PathoBiology Group of the European Organization for 
Research and Treatment of Cancer are now in the process of initiating a 
prospective study validating these findings. 
A recent publication (55) describes the association between plasma 
TIMP-1 levels and response to endocrine therapy in breast cancer. In a 
cohort of 251 patients with metastatic breast cancer treated with second 
line endocrine therapy, the objective response rate (CR+PR+SD) was 
42% in patients with low TIMP-1 levels while the objective response rate 
in TIMP-1 high patients was only 16%. This difference was also reflected 
in a significant longer time to progression and a significant longer 
survival of plasma TIMP-1 low patients. 
Clinical Validation of Predictive Markers
In order to have clinical impact, a new predictive marker has to pass a 
number of analytical and clinical validation steps (56). A major dilemma 
associated with assays for biomarkers is that various assays may employ 
different reagents (e.g. antibodies), which may generate non-equivalent 
test results. Also, variations in reagent preparations, sample processing 
and the use of different standards may result in discordant test results. 
Therefore, reagents, assays and procedures should be standardized 
and the quality of biomarker assay results should be monitored 
by continuous inter-laboratory proficiency testing of performance. 
Biomarkers are often used in the clinical setting to provide additional 
information that will influence clinical decision making, while only few 
guidelines have been established to inform about how a biomarker 
should become standard for a certain type of cancer. Hayes et al., 1996 
(57) therefore proposed that it is highly necessary to establish standard 
criteria for evaluation of biomarkers and to standardize the biomarker 
information for clinical utility. To judge whether these factors have added 
value over the traditional factors, McGuire et al, 1992 (58) proposed 
guidelines for evaluating new cancer biomarkers, including a biologic 
hypothesis for the new factor, adequate sample size, risk of sampling 
bias, appropriate test system, establishment of cut-off values in a training 
data-set and confirmation of the observation in a validation data set. 
Biomarker assay results often are quite heterogeneous, depending 
on the composition of the specimen, the way tissue is processed, 
and design and specificity of an assay and, as important, statistical 
methods used for evaluation of data. It is of utmost importance to note 
that uniform handling applies to all of the laboratory steps including 
use of highly standardized and optimized reagents, tissue collection, 
storage and processing, the analytical procedures, and subsequent 
data processing. Within Europe, a multitude of translational multi-centre 
cancer studies have been co-ordinated by the European Organisation 
for Research and Treatment of Cancer (EORTC). Within this consortium 
the PathoBiology Group was established to research and to advice on 
common, or equivalent, methodologies for biomarker assays and to 
ensure that appropriate External Quality Assessment (EQA) schemes 
are applied. As an example, for the past 25 years for ER and PgR, large-
scale EQA trials, amounting to participating 165 institutions/hospitals 
from 18 countries, have been carried out and organized by PathoBiology 
Group (59, 60). 
When a validated assay is available, the clinical studies can be initiated. 
It is recommended to start analyzing material collected from prior well-
controlled clinical studies, from which high quality sample material 
as well as clinical outcome regarding treatment efficacy is available. 
Following these retrospective studies, the prospective clinical studies 
can be started. We recommend that the first study is designed as an 
adjunct to a clinical study in which the primary objective is to test the 
efficacy of one or more drugs. In such a study, sample collection should 
be prospective and strictly follow predefined conditions (Standard 
Operating Procedures) regarding sample collection, storage handling, 
analyses and data reporting. The next step in the validation is a well-
dimensioned prospective study where the primary objective is to validate 
the predictive power of the marker in question. A simple trial design is 
as follows: Patients are randomized to receive either standard treatment 
or marker-guided treatment. End-points will be objective response rate 
(RECIST criteria’s), or time to progression and less frequent overall 
Figure 3. Schematic presentation of part of the intracellular signalling initiated 
by TIMP-1 binding to CD63
TIMP-1 and Apoptosis
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survival. This type of clinical studies can only be performed in cancer 
types for which more than one treatment option exists and is especially 
helpful if the efficacy of the different treatments is considered equal. 
For example, in the majority of patients with metastatic colorectal 
cancer (mCRC), chemotherapy is the treatment of choice. Survival 
following chemotherapy of mCRC has improved substantially over 
the last years. Whereas survival without chemotherapy was limited to 
8.5 months, the first effective drug (5-fluorouracil, 5FU) was shown to 
increase the median overall survival to 12 months (61). Addition to 5FU 
of either irinotecan or oxaliplatin increased the efficacy: If one of these 
drugs is added to 5FU, the response rates rise from approximately 
20% to approximately 50% with either the combination irinotecan/5FU 
(FOLFIRI) (62-64) or oxaliplatin/5FU (FOLFOX) (64-66). Irinotecan and 
oxaliplatin based chemotherapy differs in toxicity profile (diarrhoea and 
alopecia vs. neurotoxicity), but there is no meaningful difference with 
regard to the overall efficacy. Because efficacy and overall toxicity are 
similar in the whole patient population, both regimens are equally used 
in first line therapy. 
One unresolved problem with either of the chemotherapy combinations is 
that up to 25% of patients have tumors that are inherently resistant to the 
chosen chemotherapy schedule (FOLFOX or FOLFIRI) (67,68,69). The 
current clinical approach selects one treatment regimen over another 
based on predicted success (and to a lesser degree also toxicity) in 
large patient cohorts. Using this approach, there necessarily is a large 
fraction of individual patients who has no benefit whatsoever and may 
even suffer from the chemotherapy. These patients are unnecessarily 
exposed to treatment toxicity, and they experience disease progression, 
which affects the performance status and the capability to tolerate 
further chemotherapy. In contrast, they might rather profit from an 
alternative regimen. 
In contrast to predicting chemotherapy response, it is at present 
more important to predict chemotherapy resistance to metastatic 
colorectal cancer. If chemotherapy resistance to one type of cytotoxic 
drug could be predicted for individual patients, these patients could 
already as 1st line treatment receive the other treatment combination 
and thereby increase their chance of treatment benefit. In addition, 
such an approach would avoid the costs for approximately 2 months of 
ineffective treatment (with weekly costs of up to 500 €), and thereby be 
highly cost-effective. With the currently available evidence, there is no 
way to predict response or resistance to the given chemotherapeutic 
treatment in the individual patient, let alone any guidance to select one 
regimen instead of another one.
Thus, there is a need for research focusing on the identification and 
development including clinical implementation of predictive markers 
for each existing chemotherapeutic drug in addition to general markers 
for chemotherapy sensitivity/resistance. Also, a clear discrimination 
between diagnostic, prognostic and predictive markers is needed, 
including statistical methods that can facilitate this separation.
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